TABLE 1.
The laboratory findings before (day 23) and after the First (day 28) and Second (day 42) administrations of canakinumab.
| Variable | Before | After First | After Second |
| Hemoglobin (Hb) g/dL | 12.0 | 11.3 | 8.7 |
| White Blood Cell count (WBC) × 109/L | 4.4 | 6.5 | 12.4 |
| Neutrophils-bands (Neutroph) × 109/L | 3.4 | 5.8 | 10.3 |
| Lymphocytes (Lymph) × 109/L | 0.5 | 0.2 | 0.5 |
| Platelet count (PLT) × 109/L | 135 | 107 | 291 |
| D-dimer (D-d) nmol/L | 2.1 | 1.9 | 3.2 |
| Creatinine (Cr) μmol/L | 44 | 124 | 97 |
| CRP mg/L | 3.1 | 10.2 | 156.0 |
| Lactate dehydrogenase (LDH) μkat/L | 5.0 | 3.8 | 3.8 |
| Alkaline phosphatase μkat/L | 1.6 | 1.9 | 1.9 |
| Alanine aminotransferase (ALT) μkat/L | 1.0 | 0.5 | 0.2 |
| Aspartate aminotransferase (AST) μkat/L | 0.5 | 0.4 | 0.4 |
| γ-Glutamyltransferase (GGT) μkat/L | 0.4 | 0.4 | 0.5 |
| Serum IL-6, IU/ml | 424.6 | 46.2 | 75.2 |
| Immunophenotype, cells/μL | |||
| Lymphocyte T | |||
| CD3+ | 402 | 172 | 114 |
| CD3+CD4+ | 309 | 117 | 74 |
| CD3+CD8+ | 95 | 56 | 41 |
| Lymphocyte B CD19+ | 31 | 32 | 34 |
| Lymphocyte NK | |||
| CD16+CD56+ | 111 | 77 | 18 |
| NK CD56DIM | 57 | 66 | 109 |
| NK CD56BRIGHT | 42 | 1 | 2 |
| CD4/CD8 Ratio | 3 | 2 | 2 |